289 related articles for article (PubMed ID: 31684756)
21. Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy.
Dweck D; Sanchez-Gonzalez MA; Chang AN; Dulce RA; Badger CD; Koutnik AP; Ruiz EL; Griffin B; Liang J; Kabbaj M; Fincham FD; Hare JM; Overton JM; Pinto JR
J Biol Chem; 2014 Aug; 289(33):23097-23111. PubMed ID: 24973218
[TBL] [Abstract][Full Text] [Related]
22. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity.
Lovelock JD; Monasky MM; Jeong EM; Lardin HA; Liu H; Patel BG; Taglieri DM; Gu L; Kumar P; Pokhrel N; Zeng D; Belardinelli L; Sorescu D; Solaro RJ; Dudley SC
Circ Res; 2012 Mar; 110(6):841-50. PubMed ID: 22343711
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Analysis of Troponin C Knock-In (A8V) Mice: Evidence that TNNC1 Is a Hypertrophic Cardiomyopathy Susceptibility Gene.
Martins AS; Parvatiyar MS; Feng HZ; Bos JM; Gonzalez-Martinez D; Vukmirovic M; Turna RS; Sanchez-Gonzalez MA; Badger CD; Zorio DAR; Singh RK; Wang Y; Jin JP; Ackerman MJ; Pinto JR
Circ Cardiovasc Genet; 2015 Oct; 8(5):653-664. PubMed ID: 26304555
[TBL] [Abstract][Full Text] [Related]
24. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J
Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555
[TBL] [Abstract][Full Text] [Related]
25. Enhanced active cross-bridges during diastole: molecular pathogenesis of tropomyosin's HCM mutations.
Bai F; Weis A; Takeda AK; Chase PB; Kawai M
Biophys J; 2011 Feb; 100(4):1014-23. PubMed ID: 21320446
[TBL] [Abstract][Full Text] [Related]
26. Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice.
Huang W; Liang J; Kazmierczak K; Muthu P; Duggal D; Farman GP; Sorensen L; Pozios I; Abraham TP; Moore JR; Borejdo J; Szczesna-Cordary D
J Mol Cell Cardiol; 2014 Sep; 74():318-29. PubMed ID: 24992035
[TBL] [Abstract][Full Text] [Related]
27. Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy.
Huang Y; Lu H; Ren X; Li F; Bu W; Liu W; Dailey WP; Saeki H; Gabrielson K; Abraham R; Eckenhoff R; Gao WD
Cardiovasc Res; 2020 May; 116(6):1175-1185. PubMed ID: 31424496
[TBL] [Abstract][Full Text] [Related]
28. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.
Latif SR; Nguyen VQ; Peters DC; Soufer A; Henry ML; Grunseich K; Testani J; Hur DJ; Huber S; Mojibian H; Dicks D; Sinusas AJ; Meadows JL; Papoutsidakis N; Jacoby D; Baldassarre LA
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1309-1318. PubMed ID: 30790116
[TBL] [Abstract][Full Text] [Related]
29. Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldosterone system.
Blauwet LA; Ackerman MJ; Edwards WD; Riehle DL; Ommen SR
Cardiovasc Pathol; 2009; 18(5):262-8. PubMed ID: 18835191
[TBL] [Abstract][Full Text] [Related]
30. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity.
Rajan S; Ahmed RP; Jagatheesan G; Petrashevskaya N; Boivin GP; Urboniene D; Arteaga GM; Wolska BM; Solaro RJ; Liggett SB; Wieczorek DF
Circ Res; 2007 Jul; 101(2):205-14. PubMed ID: 17556658
[TBL] [Abstract][Full Text] [Related]
31. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
[TBL] [Abstract][Full Text] [Related]
32. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.
Nagueh SF; Chen S; Patel R; Tsybouleva N; Lutucuta S; Kopelen HA; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
J Mol Cell Cardiol; 2004 May; 36(5):663-73. PubMed ID: 15135661
[TBL] [Abstract][Full Text] [Related]
33. Divergent abnormal muscle relaxation by hypertrophic cardiomyopathy and nemaline myopathy mutant tropomyosins.
Michele DE; Coutu P; Metzger JM
Physiol Genomics; 2002; 9(2):103-11. PubMed ID: 12006676
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine-1-phosphate and its mimetic FTY720 do not protect against radiation-induced ovarian fibrosis in the nonhuman primate†.
Amargant F; Manuel SL; Larmore MJ; Johnson BW; Lawson M; Pritchard MT; Zelinski MB; Duncan FE
Biol Reprod; 2021 May; 104(5):1058-1070. PubMed ID: 33524104
[TBL] [Abstract][Full Text] [Related]
35. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes.
Wang L; Kim K; Parikh S; Cadar AG; Bersell KR; He H; Pinto JR; Kryshtal DO; Knollmann BC
J Mol Cell Cardiol; 2018 Jan; 114():320-327. PubMed ID: 29217433
[TBL] [Abstract][Full Text] [Related]
36. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties.
Jeong EM; Monasky MM; Gu L; Taglieri DM; Patel BG; Liu H; Wang Q; Greener I; Dudley SC; Solaro RJ
J Mol Cell Cardiol; 2013 Mar; 56():44-54. PubMed ID: 23247392
[TBL] [Abstract][Full Text] [Related]
37. Hypertrophic cardiomyopathy mutation in cardiac troponin T (R95H) attenuates length-dependent activation in guinea pig cardiac muscle fibers.
Mickelson AV; Chandra M
Am J Physiol Heart Circ Physiol; 2017 Dec; 313(6):H1180-H1189. PubMed ID: 28842439
[TBL] [Abstract][Full Text] [Related]
38. Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy.
Nijenkamp LLAM; Bollen IAE; van Velzen HG; Regan JA; van Slegtenhorst M; Niessen HWM; Schinkel AFL; Krüger M; Poggesi C; Ho CY; Kuster DWD; Michels M; van der Velden J
Circ Heart Fail; 2018 Jun; 11(6):e004133. PubMed ID: 29853478
[TBL] [Abstract][Full Text] [Related]
39. Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2.
Sørensen LL; Bedja D; Sysa-Shah P; Liu H; Maxwell A; Yi X; Pozios I; Olsen NT; Abraham TP; Abraham R; Gabrielson K
Comp Med; 2016; 66(4):268-77. PubMed ID: 27538857
[TBL] [Abstract][Full Text] [Related]
40. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males.
Luckey SW; Mansoori J; Fair K; Antos CL; Olson EN; Leinwand LA
Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H838-45. PubMed ID: 17012357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
